$7.89
0.75% day before yesterday
Nasdaq, Nov 26, 10:02 pm CET
ISIN
CA31447P1009
Symbol
FENC

Fennec Pharmaceuticals Inc. Stock price

$7.89
-0.93 10.54% 1M
+0.02 0.25% 6M
+1.57 24.84% YTD
+1.85 30.63% 1Y
-1.72 17.90% 3Y
+0.01 0.13% 5Y
+6.58 502.93% 10Y
-30.71 79.56% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.06 0.75%
ISIN
CA31447P1009
Symbol
FENC
Industry

Key metrics

Basic
Market capitalization
$264.0m
Enterprise Value
$260.2m
Net debt
positive
Cash
$22.0m
Shares outstanding
28.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.8 | 5.8
EV/Sales
6.7 | 5.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-13.1%
Return on Equity
7.4%
ROCE
-11.8%
ROIC
-
Debt/Equity
-4.1
Financials (TTM | estimate)
Revenue
$38.8m | $45.4m
EBITDA
- | $15.4m
EBIT
$-4.7m | $2.7m
Net Income
$-6.9m | $-2.1m
Free Cash Flow
$-7.5m
Growth (TTM | estimate)
Revenue
-21.4% | -4.5%
EBITDA
- | -
EBIT
-340.1% | 6.6%
Net Income
-615.5% | -370.5%
Free Cash Flow
-132.5%
Margin (TTM | estimate)
Gross
93.1%
EBITDA
- | 33.9%
EBIT
-12.0%
Net
-17.9% | -4.6%
Free Cash Flow
-19.4%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
5.5%
Employees
32
Rev per Employee
$1.5m
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
91%
Hold
9%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
39 39
21% 21%
100%
- Direct Costs 2.67 2.67
17% 17%
7%
36 36
22% 22%
93%
- Selling and Administrative Expenses 41 41
10% 10%
104%
- Research and Development Expense 0.28 0.28
3% 3%
1%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -4.66 -4.66
340% 340%
-12%
Net Profit -6.94 -6.94
615% 615%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast.
Neutral
GlobeNewsWire
11 days ago
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters' option to purchase additional common shares) at a pub...
Neutral
GlobeNewsWire
14 days ago
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proce...
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 32
Founded 1996
Website fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today